lexipafant

Lexipafant is a potent and selective small molecule inhibitor of the phospholipid mediator platelet-activating factor (PAF), acting as a PAF receptor antagonist. Developed in the 1990s by British Biotech, it was investigated primarily for acute pancreatitis and also considered for HIV-associated neurocognitive disorder and severe sepsis. Lexipafant demonstrated high affinity for the human platelet PAF receptor, with preclinical studies showing anti-inflammatory effects in animal models of pancreatitis and liver injury. In clinical trials, including large multicenter Phase III studies, lexipafant reduced some organ failure scores but failed to improve overall survival or reduce new organ failure rates in severe acute pancreatitis. As a result, its development as a medicine was discontinued; however, it remains used as a model PAF inhibitor in pharmacological research[1][2][3][4][5][6].

Brand names

Zacutex